Cardiovascular Outcomes- Tamoxifen trials

Trial NameNLength of Treatment (years)Length of FU (years)PlaceboTamoxifenRR95% CINotesOutcome assessment
PlaceboTamoxifenNo.RateNo.Rate
Royal Marsden
Powles 200726:
Active
12331238813.2101.25121.020.820.35–1.89p= 0.7“Cardiovasc-ular problems” not further defined.
Post1114p= 0.7
Italian
Veronesi, 200729:
Myocardial
Infarction
270827005450.4850.491.040.3–3.58
Veronesi, 200729:212.01353.481.731.01–2.98Cardiac Arrhythmias, Atrial Fibrillation
IBIS
Cuzick, 200720
CHD events
35753579596 months712.73642.371.150.81–1.64Checklist of predefined side effects asked directly during main trial
All cardiac
Active
713.98643.590.90.63–1.28Mailed questionaires during follow-up
Post524.85585.421.120.75–1.66Illnesses confirmed with record review
MI; Active70.3920.110.290.03–1.5
Post80.7570.650.880.27–2.76
NSABP
Fisher, 200523
Total CHD
67076681571092.71132.791.030.79–1.36Total CHD includes: MI, acute coronary syndrome, severe angina
Fisher, 199824
Total CHD
569 months622.37712.731.150.81–1.64
Fisher, 200523
MI
441.09431.060.970.62–1.52
Fisher, 200523
ACS
320.79360.891.120.68–1.86
Fisher, 200523
Severe angina
330.82340.841.030.62–1.71
Fisher, 199824
MI
6707668144281.07311.191.110.65–1.92

From: Appendix D, Evidence Tables

Cover of Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women
Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women [Internet].
AHRQ Comparative Effectiveness Reviews, No. 17.
Nelson HD, Fu R, Humphrey L, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.